



Regenerative Capacity of Endogenous Factor: Growth Differentiation Factor 11; a New Approach of the Management of Age-Related Cardiovascular Events

Luc Rochette, Alexandre Meloux, Eve Rigal, Marianne Zeller, Yves Cottin, Gabriel Malka, Catherine Vergely

► To cite this version:

Luc Rochette, Alexandre Meloux, Eve Rigal, Marianne Zeller, Yves Cottin, et al.. Regenerative Capacity of Endogenous Factor: Growth Differentiation Factor 11; a New Approach of the Management of Age-Related Cardiovascular Events. International Journal of Molecular Sciences, 2018, 19 (12), pp.3998. 10.3390/ijms19123998 . hal-03431597

HAL Id: hal-03431597

<https://u-bourgogne.hal.science/hal-03431597>

Submitted on 16 Nov 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Review

Regenerative Capacity of Endogenous Factor: Growth Differentiation Factor 11; a New Approach of the Management of Age-Related Cardiovascular Events

Luc Rochette ^{1,*}, Alexandre Meloux ¹, Eve Rigal ¹, Marianne Zeller ¹, Yves Cottin ^{1,2}, Gabriel Malka ³ and Catherine Vergely ¹

¹ Equipe d'Accueil (EA 7460): Physiopathologie et Epidémiologie Cérébro-Cardiovasculaires (PEC2), Université de Bourgogne – Franche Comté, Faculté des Sciences de Santé, 7 Bd Jeanne d'Arc, 21000 Dijon, France; alexandre.meloux@gmail.com (A.M.); eve.rigal@u-bourgogne.fr (E.R.); marianne.zeller@u-bourgogne.fr (M.Z.); yves.cottin@chu-dijon.fr (Y.C.); catherine.vergely@u-bourgogne.fr (C.V.)

² Service de Cardiologie—CHU-Dijon, 21 000 Dijon, France

³ Institut de formation en biotechnologie et ingénierie biomédicale (IFR2B), Université Mohammed VI Polytechnique, 43 150 Ben-Guerir, Morocco; catherine.vergely@u-bourgogne.fr

* Correspondence: luc.rochette@u-bourgogne.fr; Tel.: +33(0)-380-393-291.

Received: 16 November 2018; Accepted: 5 December 2018; Published: 12 December 2018



Abstract: Aging is a complicated pathophysiological process accompanied by a wide array of biological adaptations. The physiological deterioration correlates with the reduced regenerative capacity of tissues. The rejuvenation of tissue regeneration in aging organisms has also been observed after heterochronic parabiosis. With this model, it has been shown that exposure to young blood can rejuvenate the regenerative capacity of peripheral tissues and brain in aged animals. An endogenous compound called growth differentiation factor 11 (GDF11) is a circulating negative regulator of cardiac hypertrophy, suggesting that raising GDF11 levels could potentially treat or prevent cardiac diseases. The protein GDF11 is found in humans as well as animals. The existence of endogenous regulators of regenerative capacity, such as GDF11, in peripheral tissues and brain has now been demonstrated. It will be important to investigate the mechanisms with therapeutic promise that induce the regenerative effects of GDF11 for a variety of age-related diseases.

Keywords: GDF11; regenerative; parabiosis; cardiovascular events; ageing

1. Introduction

The prevalence of a number of chronic diseases is much higher in the elderly. These diseases include cardiovascular diseases, stroke, cancer, and dementia. There are strong similarities between the cellular changes related to aging and those found in some of the most common chronic, non-communicable, and mostly multifactorial diseases. Several major theories have been put forward to explain the biology of aging, and these are not mutually exclusive. It is now well established that cellular senescence is associated with the activation of pro-inflammatory pathways and free radical production [1]. Novel ways to diagnose aging involving telomeres and other markers of senescence are being validated. Biological factors appear as “mediators,” which can be targeted to slow down or even reverse disease or physiological conditions such as aging [2]. It is widely accepted that the rate of aging reflects the ratio of tissue attrition to tissue regeneration; it thus seems credible to assume that accelerated aging can result from an alteration of this balance, caused by either the exacerbation of tissue attrition or a defect in tissue regeneration. The human heart is a highly dynamic organ that retains a significant degree of plasticity throughout life and even in the presence of heart

failure. The reversibility of certain aspects of aging has become increasingly appreciated. The stem cell compartment appears to be properly equipped to regulate tissue homeostasis, but this function is determined by the plasticity and heterogeneity of adult stem cells [3–5].

2. Mechanistic and Evolutionary Bases of Aging

Aging is characterized by a regular functional drop of all organs. It is endogenous, progressive, and deleterious for the individual. Among all aging theories, one describes nitro-oxidative stress associated with the overproduction of reactive oxygen species (ROS) and reactive nitrogen species (RNS). It implies that progressive aging is associated with metabolic diseases [6,7].

Vascular aging is the major contributing factor to increases in the incidence and prevalence of cardiovascular disease, due mainly to the presence of chronic, low-grade inflammation. Aging produces its own cardiovascular changes, mainly remodeling of arteries and the myocardium [8]. Cardiovascular diseases (CVD), including hypertension, coronary artery disease (CAD), atrial fibrillation and chronic heart failure (CHF), are highly prevalent in the elderly. CHF associated with hypertrophy is a mounting health problem that affects up to 10% of people over the age of 65 and it is associated with frequent hospital admissions, reduced quality of life, significant morbidity, and increased mortality. Cardiac hypertrophy is considered an initially adaptive response that counteracts increased wall tension and helps maintain cardiac output. However, if the heart is persistently exposed to increased loads, cardiac hypertrophy may become maladaptive, leading to heart failure. Aging is associated with an extensive loss of function at all levels of biological organization. Studies using model organisms have generated significant insights into the genetic factors and environmental conditions that influence the age-related decline [9,10]. Progressive aging induces several structural and functional alterations in the cardiovascular system, among which a reduced number of myocardial cells and increased interstitial collagen fibers are particularly important as they result in the development of heart failure. The signals and mechanisms that cause age-related tissue failure are unclear. One of these alterations is a change in the activity of the protein kinase Akt, which plays a central role in regulating a variety of cellular processes ranging from cell survival to aging. Extensive studies have established that growth factors, hormones, and cytokines stimulate Akt activation through serial phosphorylation events. Accumulating evidence illustrates that different Akt isoforms are responsible for their diverse biological functions.

In cardiac hypertrophy and aging, sirtuins (SIRT) have been shown to regulate Akt signaling. The SIRT isoforms SIRT 1, SIRT3, and SIRT6 play a central role in the regulation of Akt activation. Although SIRT1 deacetylates Akt to promote phosphatidylinositol (3,4,5)-triphosphate binding and activation, SIRT3 controls ROS-mediated Akt activation, and SIRT6 transcriptionally represses Akt at the level of chromatin [11]. In the cardiovascular field, treatments can protect heart muscle tissue after acute myocardial infarction (MI). Post-infarction remodeling and the evolution to CHF remain a problem in the treatment of cardiovascular disorders. Tissue regeneration is characterized by composite drops of growth factors with decisive roles in cell proliferation and differentiation. [12]. Numerous trials have been started to explore the transplantation of stem-cell populations for cardiac regeneration. Although most cell types produced hopeful results in vitro and in preclinical studies, they were disappointing in terms of clinical profits [13,14].

Growth differentiation factor 11 (GDF11) belongs to the transforming growth factor β : TGF- β family. Members of the TGF- β superfamily are highly conserved across animals. They are ubiquitously expressed in diverse tissues and function during the earliest stages of development and throughout life. The TGF- β superfamily of secreted factors comprises more than 30 members including activins, nodals, bone morphogenetic proteins (BMPs), and the GDFs such as GDF11 and GDF15. TGF- β family members are involved in a wide range of functions and play key roles in embryogenesis, development, and tissue homeostasis.

GDF11, like other members of the TGF- β superfamily, are generated from precursor proteins by proteolytic processing [15]. After cleavage of a single peptide bond by a furin-type protease,

the N-terminal propeptide and the disulfide-bonded homodimer containing the mature growth factor domains remain connected, establishing an inactive and latent complex. The active mature growth factors may be released from the latent complexes beyond degradation of the propeptide via proteases [16] (Figure 1). GDF11 is a disulfide-linked dimer. It is firstly synthesized as precursor and next cleaved by furin-like proteases separating the N-terminal prodomain from the C-terminal domain.

GDF11 is expressed in the pancreas, intestine, kidney, skeletal muscle, heart, developing nervous system, olfactory system, and retina [17]. Its expression is present in young adult organs and decline during aging. In return, a study [18] demonstrated that GDF11 serum levels do not reduce during aging. The reagents used in some studies were not GDF11-specific, interfering with myostatin evaluation. The amino acid sequence of GDF11 is 90% identical to that of myostatin [19]. Recently, based on quantification by Western blot analysis, a study showed that circulating GDF11/8 levels decreased with age in mice as well as in other mammalian species, and that increasing GDF11/8 levels with exogenous GDF11 regulated cardiomyocyte size [20].

Clearly, the search for humoral factors, such as GDF11, able to affect regenerative capacity, should be re-examined [21]. Different functions of GDF11 in controlling progenitor proliferation and/or differentiation were demonstrated [22]. Experimental methods using techniques of parabiosis demonstrate that impaired regeneration in aged mice is reversible by exposure to circulation of young animals. GDF11 controls heart and muscle aging, suggesting that young blood contains “rejuvenating” factors that can renovate regenerative process.




Figure 1. Structural organization of GDF11 mature domain (A) and schematic representation of GDF11 signaling pathways (B). (A) Mature GDF11 exists as a disulfide-linked homodimer with apparent molecular weights of 25 kDa. The active domain of GDF11 is typically found as a dimer, linked by cysteine-bonds. The symmetrical dimer forms two distinct interfaces for receptor binding. All the other cysteine C are involved in intrachain disulfide bonds. As show in the schematic representation, there are four disulfide bounds in each homodimer. C plays an important role in stabilization of protein structure The LTBPs (latent transforming growth factor β binding proteins) are components of the extracellular matrix, identified as forming latent complexes with TGF- β . (B) TGF- β is associated with latent transforming growth factor B – binding proteins (LTBPs) inside the cell form the large latent complex (LLC). TGF- β is secreted in a latent dimeric complex containing the C-terminal mature TGF- β and its N-terminal pro-domain, LAP (TGF- β latency associated protein). Proteolytic activation via matrix metalloproteinases (MMPs) and reactive oxygen species (ROS) are associated with the TGF- β activation mechanism, releasing an active dimer to elicit signaling. GDF11 (active form), a TGF- β signaling factor (407 amino acids) exerts its effects by binding to specific receptors. Members of TGF- β family bind to activin-receptor-like-kinase: ALK-Type I and Type II. ALK-I induces phosphorylation of Smads. Ligands of various TGF- β receptors lead to recruitment and activation of Smads transcription factors that regulate gene expression in nucleus. Differences in GDF11 expression and cellular effects vary depending on tissue localization.

3. The Surgical Technique of Parabiosis

In order to investigate the influences of an organism on its conjoined partner, animal models that “mimic” the natural phenomenon of conjoined twins were created. The surgical technique of physically connecting two living organisms was termed “parabiosis”, from the Greek “para” (next to) and “bios” (life). Unlike transbiosis, there are no formal donors and hosts in parabiosis as each animal can be viewed as an equal partner in the pairing, each influencing the other animal called a parabiont. These methods have evolved over time and have involved the surgical connection of different body parts [23]. Use of the parabiotic model in studies of cutaneous wound healing to define the participation of circulating cells [24,25].

The technique was first introduced by the French physiologist Paul Bert in the 1860s. The surgical way involves skin incisions along the contiguous flanks of two animals (usually mice) and suturing adjacent skin flaps between the animals. The peritoneum is sutured together between the animals to form a common peritoneal cavity. The first studies started to graft animals of different ages to each other (heterochronic parabiosis (HP)) in order to investigate effects induced through exposure of an aged organism to a youthful systemic environment. In HP, the parabiotic pairing of two animals is of different ages. Parabiotic pairings between two young (Y) mice or two old (O) mice are isochronic parabiosis (IP). It is an experimental system to test for systemic effects on the process of tissue aging. Collecting verification has indicated that the blood of young animals holds powerful “factors of youth”.

4. Does GDF11 Reverse Age-Related Functional Impairment in Heart?

As we reported previously, cardiac hypertrophy is a prominent pathological feature of age-related heart failure. Using the parabiosis model, it has been demonstrated that age-related cardiac hypertrophy can be reversed via exposure to a young circulatory environment. These experiments revealed that age-related cardiac hypertrophy is at least in part mediated by circulating factors, such as GDF11, which is able to reverse the condition [26]. The authors generated HP pairs, in which Y female C57BL/6 mice (Y-HP, 2 months) were surgically joined to O-partners (O-HP, 23 months), and compared these with IP pairs (Y-Y, Y-IP, or O-O, O-IP), joined at identical ages, and to age- and sex-matched unpaired mice as controls. Parabiotic pairs were continued for 4 weeks before analysis. The hearts from old mice exposed to a young circulation (O-HP) for these 4 weeks were patently smaller than hearts from O-IP mice. The reduction of cardiac hypertrophy was associated with changes in cellular hypertrophy. This effect is evaluated by morphometric analysis of cardiac histologic sections. The reversal of cardiac hypertrophy in old mice exposed to a young circulation cannot be explained by a reduction in blood pressure in the older mice. An extensive proteomics analysis was performed on the serum and plasma of the animals. GDF11 was reduced in the circulation of aged mice and its levels were restored to those in young animals by HP. A significant decrease was also found in both GDF11 gene expression and GDF11 protein levels in the spleens of old mice. These results suggest exciting therapeutic approaches for the management of age-related cardiac hypertrophy by restoring youthful levels of circulating GDF11. Much work remains to be done to establish the efficacy of GDF11 as a therapeutic rejuvenation factor [27]. Recently, the goal of a study in old mice [28] was to reexamine the possibility to restore youthful levels of GDF11 by injecting rGDF11 and thus reversing cardiac hypertrophy and imparting a young phenotype to the old heart. The conclusions were that recombinant GDF11 (rGDF11) had no effect on cardiac structure and cardiac pump function; these results do not support the concept that GDF11 could be an anti-aging compound. An important study was published in the clinical cardiovascular field, analyzing the Heart and Soul and HUNT3 cohorts. It was demonstrated, in patients with stable ischemic heart disease, that higher GDF11/8 levels were associated with a lower risk of cardiovascular events and death, suggesting cardioprotective properties of GDF11/8 [29].

Various studies have identified a second factor in blood from mice that mediates rejuvenating actions, a chemokine: C-C motif chemokine 1, CCL11 [30]. CCL11 is also known as eosinophil chemotactic protein. In contrast to GDF11, levels of CCL11 increase with age (Figure 2). Increased

circulating levels of CCL11 have been implicated in diseases associated with abnormal central nervous system function, including Alzheimer disease [31].




Figure 2. Age-related functional impairment in the heart, skeletal muscle, and brain—regenerative pathways. Systemic factors can affect aging-associated events, either positively or negatively. “Pro-youthful” factors, such as GDF11, present in young or aged blood may be able to improve cardiac regeneration. Another factor in blood is the chemokine (C-C motif) chemokine 11: CCL11. Age-related heart failure can be reversed by exposure to GDF11. During aging, there is a significant decline in skeletal muscle regenerative function and muscle satellite cells are responsible for the regeneration capacity of the muscle. Age-related mechanisms impair the function of the neurovascular unit in the brain. Foxo, SIRT, GDF11, and reactive oxygen species are modulators of the age-related process.

In the cardiovascular field, it is important to note the complex interplay of various cytokines in maintaining normal hematopoiesis. The process of differentiation of hematopoietic stem cells into mature blood cells is tightly regulated by the actions of both stimulatory and inhibitory cytokines. Recent studies suggest a new pathway for the treatment of anemia by targeting a newly discovered regulator of erythropoiesis via GDF11 [32].

GDF11 (active form: 407 amino-acids) exerts its effects by binding to specific receptors. Members of the TGF- β family bind to acting receptor-like-kinases: ALK-Type I and Type II. ALK-I induces phosphorylation of Smads (Figure 1). Studies reported that GDF11 Activin-type II receptors B(ActRIIB)-Smad2/3-dependent signaling is a key regulatory mechanism in proliferating erythroid precursors as it controls their late-stage maturation. New observations suggest that ActRIIA ligand traps may have therapeutic relevance in diseases such as beta-thalassemia by suppressing the deleterious effects of GDF11 [33]. The cycle is associated with changes in iron utilization caused by the decreased expression of hepcidin, the hormone that regulates iron uptake [34].

5. Does GDF11 Reverse Age-Related Functional Impairment in Skeletal Muscle?

Evidence indicates that skeletal muscle influences systemic aging. An age-dependent decline in skeletal muscle mass, strength, and endurance during the aging process is a physiological development and several factors may exacerbate this process. Capillaries are an integral part of the mechanism underlying this close matching between blood flow and metabolism of skeletal muscle mass. Capillaries have the capacity to play an active role in co-ordination of muscle blood flow responses to changed muscle metabolism [35].

Adult skeletal muscle possesses extraordinary regeneration capacities. Muscle satellite cells are responsible for the postnatal growth and major regeneration capacity of adult skeletal muscle. Aged serum increased the myogenic-to-fibrogenic conversion of young cells, whereas young serum had the opposite effect on aged cells [36]. The number of satellite cells is decreased during ageing, resulting in the attenuation of muscle regeneration capacity [37]. Several growth factors and cytokines such as TGF- β , and myostatin regulate muscle growth and repair [38,39]. Previous studies demonstrated that impaired regeneration in aged muscle can be reversed by HP, which exposes aged tissues to a youthful systemic environment and restores injury-induced satellite cell activation by the up-regulation of Notch signaling [40]. To determine whether supplementation of GDF11 from the young partner might underlie changes in skeletal muscle in heterochronic parabionts, aged mice were treated with daily intraperitoneal injections of rGDF11 to increase systemic GDF11 levels [41]. After 4 weeks, satellite cell frequency, determined by flow cytometry, and function increased in the muscles of rGDF11-treated mice, whereas other myofiber-associated mononuclear cell populations were unaffected. Aged mice treated with rGDF11 also showed increased numbers of satellite cells with intact DNA. These results indicate that GDF11 is able to regulate muscle aging and may be therapeutically suitable for skeletal muscle dysfunction.

6. Does GDF11 Reverse Age-Related Functional Impairment in Brain? Importance of the Neurovascular Unit

Normal human aging is a complex biological process that results from gradual phenotypic and functional changes of cells, which may be influenced by changes in their tissue microenvironment that occur with time. It has been demonstrated that alterations in brain structure and function are intimately tied to alterations in cognitive function. Age-related mechanisms impair the function of cells of the neurovascular unit. The brain must rely on the circulation for continuous supply of nutrients and oxygen, and for liberating metabolic spare products [42].

In humans and mice, the hippocampus and the hypothalamus are particularly vulnerable to aging. In addition to age-related differences in white and gray matter integrity, there is some evidence that age is associated with changes in the vascular system [43,44]. Older adults often have less activity in some regions, such as medial temporal areas during memory processing and visual regions across a variety of cognitive domains. A growing body of evidence shows that changes in the phenotypic and functional properties of human adult stem/progenitor cells may occur during aging and are associated with pathological consequences. Regeneration activity declines with age with the loss of stem/progenitor cell function. The brain is one of the organs that harbor a very small subpopulation of adult stem/progenitor cells, corresponding to about 0.1–3% of the total cell mass. Molecular mechanisms that may contribute to extending the longevity of adult stem/progenitor cells include their high telomerase activity, slow division, and high resistance to internal and external injuries [45].

Novel therapeutic approaches with multiple applications in humans have been conceived to reverse this chronological decline. These approaches include therapeutic strategies such as gene therapies and cell-replacement by using functional adult stem/progenitor cells [46]. Many pro-longevity signaling pathways, such as class O of forkhead box (Foxo) transcription factors and SIRT1, have been shown to play important roles in brain function. The manipulation of signaling molecules that impact Foxo and SIRT1 activities improved neuronal stress response capabilities to ROS and extended overall lifespan [47].

As we noted previously, several studies have reported that aged mice exposed to a young systemic environment exhibited reduced signs of biological aging in cardiovascular and skeletal muscle systems. The rejuvenating effects of young blood have now also been observed in the central nervous system of old mice. The rejuvenation of brain regeneration in aging organisms has been observed after HP. It has been reported that blood-borne factors, such as the chemokine CCL11, present in the systemic milieu were able to inhibit or promote adult neurogenesis in an age-dependent fashion in mice [48]. In a mouse model of demyelination, exposure of old mice to a youthful systemic environment increased myelination in the spinal cord of old heterochronic parabionts by recruiting young peripheral monocytes and promoting differentiation of oligodendrocyte progenitor cells [49]. Research has been done on whether or not the age-related decline in neurogenic function could be restored by extrinsic young signals, using a mouse heterochronic parabiosis model. It was demonstrated that aged cerebral vasculature was remodeled in response to young systemic factors, producing noticeably greater blood flow, associated with an activation of subventricular zone neural stem cell proliferation and enhanced olfactory neurogenesis, leading to an improvement in olfactory function. GDF11 was able to increase blood flow and neurogenesis in aged mice. In the context of aging, GDF11 appears to promote plasticity of the central nervous system [50]. It has been reported that old mice that received repeated injections of plasma from young animals exhibited increased learning and memory compared with old mice that received injections of old plasma. Structural and cognitive enhancements elicited by exposure to young blood are mediated, in part, by activation of the cyclic AMP response element binding protein in the aged hippocampus [30].

Cell culture experiments suggest that neurogenic rejuvenation is due to rGDF11-induced activation of the TGF- β signaling pathway in brain capillary endothelial cells, thus increasing their proliferation [50]. Ligand-receptor interactions in the TGF- β superfamily have been extensively studied. Biochemical experiments have demonstrated that GDF11 can activate Smad2, suggesting the involvement of ALK receptors in GDF11 signaling (Figure 1). It is important to recall that signaling through activin receptors is a therapeutic target in multiple diseases [51].

As previously reported, neurons, blood vessels, and neuroglia constitute the neurovascular unit. This unit appears fundamental for the brain metabolism and is regulated by numerous endogenous modulators. Recent evidence supports the hypothesis that, during inflammation, TGF- β can have an effect on the brain-wide pathway for fluid transport in the brain. The inhibition of inflammation appears to be a potential therapeutic strategy for neuro-inflammatory injury [52]. In this context, the role of GDF11 may be evoked; new investigations are required to determine the specific actions of GDF11 on the neurovascular unit and the blood–brain barrier permeability.

7. Limits and Criticism Concerning the Properties of GDF11: What is the Specificity of the Actions of GDF11?

As we reported, there is a high degree of identity between the GDF8/myostatin and GDF11 active domains. Like myostatin, the GDF11 protein is detectable in human serum [29] and signals through the activating receptors. GDF11 and GDF8 activate the same receptors. ActRIIB mediates multiple signals for TGF-beta family members, including activin, GDF8, and GDF11 [53]. As GDF11 and GDF8 are highly homologous, they are difficult to distinguish biochemically and by most commercial antibodies. When systemic GDF11 levels were evaluated without myostatin cross-reactivity, they were found to be 500 \times lower than those of myostatin. It has been suggested that reagents used in some studies were inadequate to determine whether GDF11 levels in old mice fell or increased after rGDF11 injection. It is important to use an assay with appropriate sensitivity and specificity for GDF11 detection [54].

A component of understanding the functional role of myostatin or GDF11 can be gleaned from studies of genetically modified mice. Genetic deficiency of GDF11 in mice causes profound developmental abnormalities, including agenesis of the kidneys and perinatal lethality [55,56]. The deletion of myostatin via gene targeting promoted both hypertrophy and hyperplasia of skeletal muscle, whereas postnatal inhibition of myostatin induced hypertrophy only [57]. In a study using

double myostatin, GDF11 mutants demonstrated that myostatin and GDF11 are both required for limb development and axial skeletal development and patterning. The effect of deletion of both factors on the axial skeleton was greater than for the loss of GDF11 alone. These results provide evidence that that myostatin and GDF11 have redundant functions in regulating skeletal development [58].

The potential role of GDF11 on skeletal muscle and heart should be viewed with caution according to the various and major properties of myostatin on skeletal cells. As we reported, knock-out (KO) mouse studies suggest myostatin affects skeletal muscle mass and also cardiac growth. However, the cardiac consequences of inhibiting myostatin remain unclear. Myostatin is a potent negative regulator of skeletal muscle growth and its inactivation can induce skeletal muscle hypertrophy, while its overexpression or systemic administration causes muscle atrophy [59]. GDF11 and activins exert an inhibitory effect on myocyte differentiation, similar to that induced by myostatin, and their activity is neutralized by follistatin [60].

Many questions remain about the role of the extracellular matrix and stem cells on muscle development, and factors determining the early differentiation of myogenic cells. Induced pluripotent stem (iPS) cells can be differentiated into cardiomyocytes, suggesting that iPS cells have the potential to significantly advance future cardiac regenerative therapies. The TGF- β signaling pathway is one of the important regulators of pluripotency. In this context, it is suggested that a lack of myostatin epigenetically reprograms the muscle derived stem cells (MDSCs) to become pluripotent stem cells. MDSCs are multipotent stem cells that can differentiate into skeletal muscle precursor cells [61]. Favorable effects of stem cells on perfusion and myocardial blood flow have been reported in a number of trials of cell therapy. Combining different types of stem cells lead to superior outcome in eliciting cardiac repair. Emerging approaches, including genetic modification, stem cell-derived exosomes, and new pharmacological drugs, have been applied to improve the efficacy of stem cell therapy [62]. It will be important to investigate the mechanisms that induce the myogenic effects of GDF11 with therapeutic possibilities for a variety of age-related diseases in association with cell therapy.

8. Summary

At a mechanistic level, evidence now exists that the beneficial effects of young blood on cognitive performance and cardiovascular function may be mediated by various rejuvenating factors and that many of the pro-longevity signaling pathways play important roles in organ functions. An important set of molecular mediators of regenerative capacity are those implicated in the TGF- β pathway [63] and hormones such as oxytocin [64]. At the level of cellular mechanisms, systemic inhibition of the TGF-beta type1 receptor enhanced both neurogenesis and myogenesis and normalized beta-2 microglobulin (B2M). Systemic B2M accumulation in aging blood promotes age-related cognitive dysfunction and impairs neurogenesis [65]. Furthermore, studies suggested that B2M could be a biomarker for CAD, with B2M being a predictor of all-cause mortality and adverse cardiac events in patients [66].

In conclusion, HP and old plasma administration studies have demonstrated the existence of “pro-aging” factors, such as negative regulators of regenerative capacity in peripheral tissues and the brain, and that impaired regenerative capacity is associated with alterations in cardiovascular and cognitive functions [67]. It will also be important to determine whether long-term treatment with rGDF11 has any negative consequences, especially since GDF11 is known to regulate cell proliferation in the development of multiple organ systems. The existence of possible field cancerization should be taken into consideration.

Author Contributions: All authors participated in the research and writing of the review.

Funding: This work was supported by grants from the French Ministry of Research, the Institut National de la Santé et de la Recherche Médicale (INSERM), the Regional Council of Burgundy (Conseil Régional de Bourgogne), FEDER, and the Association de Cardiologie de Bourgogne.

Acknowledgments: The authors wish to thank Philip Bastable for English assistance.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

ACVR1B	Activin receptor type IIB
ALK	Acting receptor-like-kinase
B2M	Beta-2 microglobulin
BMP	Bone morphogenetic proteins
CAD	Coronary artery disease
CCL11	C-C motif chemokine 1
CHF	Cardiac heart failure
CNS	Central nervous system
CVD	Cardiovascular disease
Foxo	Class O of forkhead box
GDF	Growth differentiation factor
HP	Heterochronic parabiotic
IP	Isochronic parabiotic
IPs	Induced pluripotent stem
MDSCs	Muscle derived stem cells
MI	Myocardial infarction
MMPs	Matrix metalloproteinases
ROS	Reactive oxygen species
RNS	Reactive nitrogen species
SIRT	Sirtuin
TGF	Transforming growth factor

References

- Franceschi, C.; Bonafe, M.; Valensin, S.; Olivieri, F.; De Luca, M.; Ottaviani, E.; De Benedictis, G. Inflamm-aging. An evolutionary perspective on immunosenescence. *Ann. N. Y. Acad. Sci.* **2000**, *908*, 244–254. [[CrossRef](#)] [[PubMed](#)]
- Newgard, C.B.; Sharpless, N.E. Coming of age: Molecular drivers of aging and therapeutic opportunities. *J. Clin. Investig.* **2013**, *123*, 946–950. [[CrossRef](#)] [[PubMed](#)]
- Freije, J.M.; Lopez-Otin, C. Reprogramming aging and progeria. *Curr. Opin. Cell Biol.* **2012**, *24*, 757–764. [[CrossRef](#)] [[PubMed](#)]
- Rota, M.; Leri, A.; Anversa, P. Human heart failure: Is cell therapy a valid option? *Biochem. Pharmacol.* **2014**, *88*, 129–138. [[CrossRef](#)] [[PubMed](#)]
- Leri, A.; Rota, M.; Hosoda, T.; Goichberg, P.; Anversa, P. Cardiac stem cell niches. *Stem Cell Res.* **2014**, *13*, 631–646. [[CrossRef](#)] [[PubMed](#)]
- Oudot, A.; Martin, C.; Busseuil, D.; Vergely, C.; Demaison, L.; Rochette, L. NADPH oxidases are in part responsible for increased cardiovascular superoxide production during aging. *Free Radic. Biol. Med.* **2006**, *40*, 2214–2222. [[CrossRef](#)] [[PubMed](#)]
- Rochette, L.; Lorin, J.; Zeller, M.; Guillard, J.C.; Lorgis, L.; Cottin, Y.; Vergely, C. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: Possible therapeutic targets? *Pharmacol. Ther.* **2013**, *140*, 239–257. [[CrossRef](#)]
- Cheitlin, M.D. Cardiovascular physiology-changes with aging. *Am. J. Geriatr. Cardiol.* **2003**, *12*, 9–13. [[CrossRef](#)]
- Demontis, F.; Piccirillo, R.; Goldberg, A.L.; Perrimon, N. The influence of skeletal muscle on systemic aging and lifespan. *Aging Cell* **2013**, *12*, 943–949. [[CrossRef](#)]
- Wang, L.; Karpac, J.; Jasper, H. Promoting longevity by maintaining metabolic and proliferative homeostasis. *J. Exp. Biol.* **2014**, *217*, 109–118. [[CrossRef](#)]
- Pillai, V.B.; Sundaresan, N.R.; Gupta, M.P. Regulation of Akt signaling by sirtuins: Its implication in cardiac hypertrophy and aging. *Circ. Res.* **2014**, *114*, 368–378. [[CrossRef](#)] [[PubMed](#)]
- Segers, V.F.; Lee, R.T. Protein therapeutics for cardiac regeneration after myocardial infarction. *J. Cardiovasc. Transl. Res.* **2010**, *3*, 469–477. [[CrossRef](#)] [[PubMed](#)]

13. Haider, H.; Lei, Y.; Ashraf, M. MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases. *Curr. Opin. Mol. Ther.* **2008**, *10*, 611–621. [[PubMed](#)]
14. Sanganalath, S.K.; Bolli, R. Cell therapy for heart failure: A comprehensive overview of experimental and clinical studies, current challenges, and future directions. *Circ. Res.* **2013**, *113*, 810–834. [[CrossRef](#)] [[PubMed](#)]
15. Rochette, L.; Zeller, M.; Cottin, Y.; Vergely, C. Growth and differentiation factor 11 (GDF11): Functions in the regulation of erythropoiesis and cardiac regeneration. *Pharmacol. Ther.* **2015**, *156*, 26–33. [[CrossRef](#)] [[PubMed](#)]
16. Kondas, K.; Szlama, G.; Nagy, A.; Trexler, M.; Patthy, L. Biological functions of the WAP domain-containing multidomain proteins WFIKKN1 and WFIKKN2. *Biochem. Soc. Trans.* **2011**, *39*, 1416–1420. [[CrossRef](#)] [[PubMed](#)]
17. McPherron, A.C. Metabolic Functions of Myostatin and Gdf11. *Immunol. Endocr. Metab. Agents Med. Chem.* **2010**, *10*, 217–231. [[CrossRef](#)] [[PubMed](#)]
18. Egerman, M.A.; Cadena, S.M.; Gilbert, J.A.; Meyer, A.; Nelson, H.N.; Swalley, S.E.; Mallozzi, C.; Jacobi, C.; Jennings, L.L.; Clay, I.; et al. GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration. *Cell Metab.* **2015**, *22*, 164–174. [[CrossRef](#)]
19. Dschietzig, T.B. Myostatin—From the Mighty Mouse to cardiovascular disease and cachexia. *Clin. Chim. Acta Int. J. Clin. Chem.* **2014**, *433*, 216–224. [[CrossRef](#)]
20. Poggioli, T.; Vujic, A.; Yang, P.; Macias-Trevino, C.; Uygur, A.; Loffredo, F.S.; Pancoast, J.R.; Cho, M.; Goldstein, J.; Tandias, R.M.; et al. Circulating Growth Differentiation Factor 11/8 Levels Decline With Age. *Circ. Res.* **2016**, *118*, 29–37. [[CrossRef](#)]
21. Brun, C.E.; Rudnicki, M.A. GDF11 and the Mythical Fountain of Youth. *Cell Metab.* **2015**, *22*, 54–56. [[CrossRef](#)] [[PubMed](#)]
22. Kim, J.; Wu, H.H.; Lander, A.D.; Lyons, K.M.; Matzuk, M.M.; Calof, A.L. GDF11 controls the timing of progenitor cell competence in developing retina. *Science* **2005**, *308*, 1927–1930. [[CrossRef](#)] [[PubMed](#)]
23. Conboy, M.J.; Conboy, I.M.; Rando, T.A. Heterochronic parabiosis: Historical perspective and methodological considerations for studies of aging and longevity. *Aging Cell* **2013**, *12*, 525–530. [[CrossRef](#)] [[PubMed](#)]
24. Song, G.; Nguyen, D.T.; Pietramaggiore, G.; Scherer, S.; Chen, B.; Zhan, Q.; Ogawa, R.; Yannas, I.V.; Wagers, A.J.; Orgill, D.P.; et al. Use of the parabiotic model in studies of cutaneous wound healing to define the participation of circulating cells. *Wound Repair Regen.* **2010**, *18*, 426–432. [[CrossRef](#)] [[PubMed](#)]
25. Kamran, P.; Sereti, K.I.; Zhao, P.; Ali, S.R.; Weissman, I.L.; Ardehali, R. Parabiosis in mice: A detailed protocol. *J. Vis. Exp. JoVE* **2013**. [[CrossRef](#)] [[PubMed](#)]
26. Loffredo, F.S.; Steinhauser, M.L.; Jay, S.M.; Gannon, J.; Pancoast, J.R.; Yalamanchi, P.; Sinha, M.; Dall'Osso, C.; Khong, D.; Shadrach, J.L.; et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. *Cell* **2013**, *153*, 828–839. [[CrossRef](#)] [[PubMed](#)]
27. Mendelsohn, A.R.; Larrick, J.W. Rejuvenation of aging hearts. *Rejuven. Res.* **2013**, *16*, 330–332. [[CrossRef](#)] [[PubMed](#)]
28. Smith, S.C.; Zhang, X.; Zhang, X.; Gross, P.; Starosta, T.; Mohsin, S.; Franti, M.; Gupta, P.; Hayes, D.; Myzithras, M.; et al. GDF11 does not rescue aging-related pathological hypertrophy. *Circ. Res.* **2015**, *117*, 926–932. [[CrossRef](#)]
29. Olson, K.A.; Beatty, A.L.; Heidecker, B.; Regan, M.C.; Brody, E.N.; Foreman, T.; Kato, S.; Mehler, R.E.; Singer, B.S.; Hveem, K.; et al. Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: Analysis of the Heart and Soul and HUNT3 cohorts. *Eur. Heart J.* **2015**, *36*, 3426–3434. [[CrossRef](#)]
30. Villeda, S.A.; Plambeck, K.E.; Middeldorp, J.; Castellano, J.M.; Mosher, K.I.; Luo, J.; Smith, L.K.; Bieri, G.; Lin, K.; Berdnik, D.; et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. *Nat. Med.* **2014**, *20*, 659–663. [[CrossRef](#)]
31. Leung, R.; Proitsi, P.; Simmons, A.; Lunnon, K.; Guntert, A.; Kronenberg, D.; Pritchard, M.; Tsolaki, M.; Mecocci, P.; Kloszewska, I.; et al. Inflammatory proteins in plasma are associated with severity of Alzheimer's disease. *PLoS ONE* **2013**, *8*, e64971. [[CrossRef](#)] [[PubMed](#)]
32. Suragani, R.N.; Cadena, S.M.; Cawley, S.M.; Sako, D.; Mitchell, D.; Li, R.; Davies, M.V.; Alexander, M.J.; Devine, M.; Loveday, K.S.; et al. Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. *Nat. Med.* **2014**, *20*, 408–414. [[CrossRef](#)] [[PubMed](#)]
33. Dussiot, M.; Maciel, T.T.; Fricot, A.; Chartier, C.; Negre, O.; Veiga, J.; Grapton, D.; Paubelle, E.; Payen, E.; Beuzard, Y.; et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in beta-thalassemia. *Nat. Med.* **2014**, *20*, 398–407. [[CrossRef](#)] [[PubMed](#)]

34. Rochette, L.; Gudjoncik, A.; Guenancia, C.; Zeller, M.; Cottin, Y.; Vergely, C. The iron-regulatory hormone hepcidin: A possible therapeutic target? *Pharmacol. Ther.* **2015**, *146*, 35–52. [[CrossRef](#)] [[PubMed](#)]
35. Murrant, C.L.; Sarelius, I.H. Coupling of muscle metabolism and muscle blood flow in capillary units during contraction. *Acta Physiol. Scand.* **2000**, *168*, 531–541. [[CrossRef](#)] [[PubMed](#)]
36. Brack, A.S.; Conboy, M.J.; Roy, S.; Lee, M.; Kuo, C.J.; Keller, C.; Rando, T.A. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. *Science* **2007**, *317*, 807–810. [[CrossRef](#)]
37. Motohashi, N.; Asakura, A. Muscle satellite cell heterogeneity and self-renewal. *Front. Cell Dev. Biol.* **2014**, *2*, 1. [[CrossRef](#)] [[PubMed](#)]
38. Burks, T.N.; Cohn, R.D. Role of TGF-beta signaling in inherited and acquired myopathies. *Skeletal Muscle* **2011**, *1*, 19. [[CrossRef](#)]
39. Brooks, N.E.; Myburgh, K.H. Skeletal muscle wasting with disuse atrophy is multi-dimensional: The response and interaction of myonuclei, satellite cells and signaling pathways. *Front. Physiol.* **2014**, *5*, 99. [[CrossRef](#)]
40. Conboy, I.M.; Conboy, M.J.; Wagers, A.J.; Girma, E.R.; Weissman, I.L.; Rando, T.A. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. *Nature* **2005**, *433*, 760–764. [[CrossRef](#)]
41. Sinha, M.; Jang, Y.C.; Oh, J.; Khong, D.; Wu, E.Y.; Manohar, R.; Miller, C.; Regalado, S.G.; Loffredo, F.S.; Pancoast, J.R.; et al. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. *Science* **2014**, *344*, 649–652. [[CrossRef](#)] [[PubMed](#)]
42. Tarantini, S.; Tran, C.H.T.; Gordon, G.R.; Ungvari, Z.; Csizsar, A. Impaired neurovascular coupling in aging and Alzheimer's disease: Contribution of astrocyte dysfunction and endothelial impairment to cognitive decline. *Exp. Gerontol.* **2017**, *94*, 52–58. [[CrossRef](#)] [[PubMed](#)]
43. Hillary, F.G.; Biswal, B. The influence of neuropathology on the fMRI signal: A measurement of brain or vein? *Clin. Neuropsychol.* **2007**, *21*, 58–72. [[CrossRef](#)] [[PubMed](#)]
44. Grady, C.L. Cognitive neuroscience of aging. *Ann. N. Y. Acad. Sci.* **2008**, *1124*, 127–144. [[CrossRef](#)] [[PubMed](#)]
45. Flores, I.; Canela, A.; Vera, E.; Tejera, A.; Cotsarelis, G.; Blasco, M.A. The longest telomeres: A general signature of adult stem cell compartments. *Genes Dev.* **2008**, *22*, 654–667. [[CrossRef](#)] [[PubMed](#)]
46. Mimeault, M.; Batra, S.K. Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications. *Ageing Res. Rev.* **2009**, *8*, 94–112. [[CrossRef](#)]
47. Lee, K.S.; Iijima-Ando, K.; Iijima, K.; Lee, W.J.; Lee, J.H.; Yu, K.; Lee, D.S. JNK/FOXO-mediated neuronal expression of fly homologue of peroxiredoxin II reduces oxidative stress and extends life span. *J. Biol. Chem.* **2009**, *284*, 29454–29461. [[CrossRef](#)]
48. Villeda, S.A.; Luo, J.; Mosher, K.I.; Zou, B.; Britschgi, M.; Bieri, G.; Stan, T.M.; Fainberg, N.; Ding, Z.; Eggel, A.; et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. *Nature* **2011**, *477*, 90–94. [[CrossRef](#)]
49. Ruckh, J.M.; Zhao, J.W.; Shadrach, J.L.; van Wijngaarden, P.; Rao, T.N.; Wagers, A.J.; Franklin, R.J. Rejuvenation of regeneration in the aging central nervous system. *Cell Stem Cell* **2012**, *10*, 96–103. [[CrossRef](#)]
50. Katsimpardi, L.; Litterman, N.K.; Schein, P.A.; Miller, C.M.; Loffredo, F.S.; Wojtkiewicz, G.R.; Chen, J.W.; Lee, R.T.; Wagers, A.J.; Rubin, L.L. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. *Science* **2014**, *344*, 630–634. [[CrossRef](#)]
51. Tsuchida, K.; Nakatani, M.; Uezumi, A.; Murakami, T.; Cui, X. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. *Endocr. J.* **2008**, *55*, 11–21. [[CrossRef](#)] [[PubMed](#)]
52. Xiang, B.; Xiao, C.; Shen, T.; Li, X. Anti-inflammatory effects of anisalcohol on lipopolysaccharide-stimulated BV2 microglia via selective modulation of microglia polarization and down-regulation of NF-kappaB p65 and JNK activation. *Mol. Immunol.* **2018**, *95*, 39–46. [[CrossRef](#)] [[PubMed](#)]
53. Chang, H.; Brown, C.W.; Matzuk, M.M. Genetic analysis of the mammalian transforming growth factor-beta superfamily. *Endocr. Rev.* **2002**, *23*, 787–823. [[CrossRef](#)] [[PubMed](#)]
54. McNally, E.M. Questions and Answers About Myostatin, GDF11, and the Aging Heart. *Circ. Res.* **2016**, *118*, 6–8. [[CrossRef](#)] [[PubMed](#)]
55. McPherron, A.C.; Lawler, A.M.; Lee, S.J. Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11. *Nat. Genet.* **1999**, *22*, 260–264. [[CrossRef](#)] [[PubMed](#)]

56. Yu, J.; McMahon, A.P.; Valerius, M.T. Recent genetic studies of mouse kidney development. *Curr. Opin. Genet. Dev.* **2004**, *14*, 550–557. [[CrossRef](#)] [[PubMed](#)]
57. Girgenrath, S.; Song, K.; Whittemore, L.A. Loss of myostatin expression alters fiber-type distribution and expression of myosin heavy chain isoforms in slow- and fast-type skeletal muscle. *Muscle Nerve* **2005**, *31*, 34–40. [[CrossRef](#)] [[PubMed](#)]
58. McPherron, A.C.; Huynh, T.V.; Lee, S.J. Redundancy of myostatin and growth/differentiation factor 11 function. *BMC Dev. Biol.* **2009**, *9*, 24. [[CrossRef](#)] [[PubMed](#)]
59. Rodriguez, J.; Vernus, B.; Chelh, I.; Cassar-Malek, I.; Gabillard, J.C.; Hadj Sassi, A.; Seiliez, I.; Picard, B.; Bonnieu, A. Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways. *Cell. Mol. Life Sci. CMLS* **2014**, *71*, 4361–4371. [[CrossRef](#)] [[PubMed](#)]
60. Gilson, H.; Schakman, O.; Kalista, S.; Lause, P.; Tsuchida, K.; Thissen, J.P. Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. *Am. J. Physiol. Endocrinol. Metab.* **2009**, *297*, E157–E164. [[CrossRef](#)] [[PubMed](#)]
61. Bose, B.; Shenoy, P.S. Pluripotent Conversion of Muscle Stem Cells Without Reprogramming Factors or Small Molecules. *Stem Cell Rev.* **2016**, *12*, 73–89. [[CrossRef](#)] [[PubMed](#)]
62. Wang, Z.; Su, X.; Ashraf, M.; Kim, I.M.; Weintraub, N.L.; Jiang, M.; Tang, Y. Regenerative Therapy for Cardiomyopathies. *J. Cardiovasc. Transl. Res.* **2018**. [[CrossRef](#)] [[PubMed](#)]
63. Yousef, H.; Conboy, M.J.; Morgenthaler, A.; Schlesinger, C.; Bugaj, L.; Paliwal, P.; Greer, C.; Conboy, I.M.; Schaffer, D. Systemic attenuation of the TGF-beta pathway by a single drug simultaneously rejuvenates hippocampal neurogenesis and myogenesis in the same old mammal. *Oncotarget* **2015**, *6*, 11959–11978. [[CrossRef](#)] [[PubMed](#)]
64. Elabd, C.; Cousin, W.; Upadhyayula, P.; Chen, R.Y.; Chooljian, M.S.; Li, J.; Kung, S.; Jiang, K.P.; Conboy, I.M. Oxytocin is an age-specific circulating hormone that is necessary for muscle maintenance and regeneration. *Nat. Commun.* **2014**, *5*, 4082. [[CrossRef](#)] [[PubMed](#)]
65. Smith, L.K.; He, Y.; Park, J.S.; Bieri, G.; Snethlage, C.E.; Lin, K.; Gontier, G.; Wabl, R.; Plambeck, K.E.; Udeochu, J.; et al. beta2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. *Nat. Med.* **2015**, *21*, 932–937. [[CrossRef](#)] [[PubMed](#)]
66. Zhang, C.; Li, F.; Long, T.; Li, F.; Peng, L.; Xia, K.; Jing, R.; Xie, Q.; Yang, T. Beta 2-Microglobulin and the Severity of Coronary Stenosis in Patients With Acute Coronary Syndrome. *Heart Lung Circ.* **2018**. [[CrossRef](#)] [[PubMed](#)]
67. Bouchard, J.; Villeda, S.A. Aging and brain rejuvenation as systemic events. *J. Neurochem.* **2015**, *132*, 5–19. [[CrossRef](#)] [[PubMed](#)]



© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).